Triple therapy aims to shrink rectal tumors without surgery

NCT ID NCT07154316

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II trial tests whether adding immunotherapy and a COX-2 inhibitor to standard chemoradiotherapy can improve complete remission rates in people with locally advanced rectal cancer that is microsatellite stable (MSS). About 138 participants will receive either long-course or short-course radiation plus the drug combo. The goal is to see if the tumor disappears completely, potentially allowing patients to avoid surgery and keep their rectum.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capecitabine, oxaliplatin, serplulimab, celecoxib, radiation therapy
What this could lead to: If successful, this combination could offer a more effective, organ-sparing treatment for a common type of rectal cancer, potentially avoiding permanent colostomy.
What could go wrong: This is a mid-stage trial with only 138 participants, so results may not apply to all patients. Adding multiple drugs also raises the risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Anyang Tumor Hospital
RECRUITING

Anyang, Henan, 455100, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Fujian Provincial Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350000, China
The First Affiliated Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, 250014, China
Yunnan Cancer Hospital
RECRUITING

Kunming, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.